Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
aTyr Pharma, Inc. (NASDAQ: LIFE) is at the forefront of the discovery and clinical development of pioneering medicines targeting severe, rare diseases. Leveraging unique insights into physiocrine biology, a newly identified group of physiological modulators, aTyr aims to deliver breakthrough treatments to patients in need.
The company's flagship candidate, resolaris™, is a first-in-class intravenous protein therapeutic designed to address rare myopathies with an immune component. Resolaris™ is undergoing a series of Phase 1b/2 clinical trials, including trials for adult patients with facioscapulohumeral muscular dystrophy (FSHD), limb girdle muscular dystrophy (LGMD) 2B or FSHD, and patients with an early onset form of FSHD.
aTyr Pharma holds a substantial intellectual property portfolio, featuring 70 issued or allowed patents and over 240 pending patent applications, all of which are solely owned or exclusively licensed by the company. This robust IP estate underpins their strategic focus on severe, rare diseases characterized by immune dysregulation.
One of the company’s notable recent achievements includes the development of efzofitimod, a first-in-class NRP2-targeting immunomodulator. Preclinical models have demonstrated that efzofitimod has significant immune regulatory functions, improving disease outcomes and mitigating fibrosis, particularly in rheumatoid arthritis and associated lung fibrosis.
In addition to its innovative drug pipeline, aTyr Pharma has bolstered its leadership and expertise by enlisting Dr. Frederick to guide corporate affairs and commercial strategies for efzofitimod in interstitial lung disease (ILD).
For the most current updates and detailed information, investors can contact Ashlee Dunston, Director of Investor Relations and Public Affairs, at adunston@atyrpharma.com.
aTyr Pharma (Nasdaq: LIFE) has identified receptor targets for two tRNA synthetases, paving the way for new therapies targeting cancer and fibrosis. This discovery is significant as it enhances understanding of extracellular tRNA synthetases' roles in disease and informs future drug development. The findings were achieved through collaboration with CSL Behring. CEO Sanjay Shukla highlighted this as a major milestone in their drug discovery efforts.
aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, is set to report its third quarter 2020 financial results and provide a corporate update on November 12, 2020, after market close. The company is focused on the discovery and development of innovative medicines utilizing novel biological pathways, particularly through its lead product candidate, ATYR1923, aimed at treating inflammatory lung diseases. A conference call and webcast will take place on the same day at 5:00 p.m. EST.
aTyr Pharma announced a research collaboration with the Medical University of South Carolina to advance its neuropilin-2 (NRP2) antibody program in oncology. Led by Dr. Robert Gemmill, the collaboration seeks to develop therapeutic antibodies targeting specific NRP2 isoforms, particularly in lung cancer, which is characterized by high NRP2 expression correlating with poor outcomes. aTyr aims to leverage this partnership to enhance therapeutic strategies against lung cancer, addressing a significant medical need amid rising drug resistance in aggressive cases.
aTyr Pharma (Nasdaq: LIFE) announced that its President and CEO, Sanjay S. Shukla, will participate in a panel discussion titled, “Immune Modulators to Ameliorate COVID-19” during the ROTH Capital Partners Webinar on October 28, 2020. This webinar will focus on COVID-19 therapeutics in development and aims to explore innovative treatments.
The event is scheduled from 9:00 a.m. to 10:20 a.m. Eastern Time. Registration is available on aTyr's website, and a replay will follow.
aTyr Pharma, Inc. (Nasdaq: LIFE) has successfully completed enrollment in its Phase 2 clinical trial of ATYR1923, targeting COVID-19 patients with severe respiratory complications. The trial enrolled 32 patients, surpassing the initial goal of 30. Results are anticipated by the fourth quarter of 2020. ATYR1923 aims to address excessive inflammatory responses in the lungs, offering a potential treatment where few options exist. The study is a double-blind, placebo-controlled trial, evaluating safety and efficacy through key clinical outcomes over a 60-day follow-up period.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) announced participation in two virtual investor events this October. CEO Sanjay S. Shukla will engage in a Q&A webinar on October 12 at 12:00pm ET, part of the ROTH Capital Partners’ CEO Talk Series. CFO Jill M. Broadfoot will present a corporate overview at the BIO Investor Forum Digital from October 13-15. aTyr focuses on developing innovative medicines based on tRNA synthetases, particularly its clinical-stage candidate ATYR1923 for inflammatory lung diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced a $20 million Common Stock Purchase Agreement with Aspire Capital on Sept. 14, 2020. The agreement allows Aspire Capital to purchase shares over a span of 30 months, with timing controlled by aTyr. This deal provides aTyr with flexible capital access to support its clinical programs, including ATYR1923 for pulmonary sarcoidosis and COVID-19 complications. Notably, aTyr retains the option to terminate the agreement without penalty. The funding aims to enhance its innovative therapies focused on immunological pathways.
aTyr Pharma (Nasdaq: LIFE) announced its participation in two key investor conferences in September 2020. Sanjay S. Shukla, M.D., President and CEO, will provide updates at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 10:30 a.m. ET and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 10:50 a.m. ET. Both events will be held virtually, and presentations will be available for replay on the company's website for 90 days post-event.
aTyr Pharma, Inc. (Nasdaq: LIFE) reported its second quarter results, noting a positive shift in enrollment for the Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis despite initial COVID-19 disruptions. A Phase 2 trial for ATYR1923 in COVID-19 patients with severe respiratory issues has commenced with promising initial safety results. Financially, total revenues reached $8.3 million for the first half of 2020, largely due to license agreements, while R&D expenses rose to $8.0 million driven by clinical activities. Cash reserves stood at $41.4 million as of June 30, 2020.
aTyr Pharma has announced that its partner, Kyorin Pharmaceutical, has initiated clinical development for ATYR1923 in Japan after receiving approval from the PMDA. The Phase 1 study will focus on safety, pharmacokinetics, and immunogenicity in healthy volunteers. aTyr received an $8 million upfront payment and could earn up to $167 million in milestone payments, along with tiered royalties on sales in Japan. aTyr is also enrolling a Phase 1b/2a trial for pulmonary sarcoidosis and a Phase 2 trial for COVID-19 patients experiencing severe respiratory issues.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
What does aTyr Pharma, Inc. specialize in?
What is aTyr Pharma's leading drug candidate?
In which clinical trial phases is resolaris™ currently?
What is the significance of physiocrine biology for aTyr Pharma?
How strong is aTyr Pharma's intellectual property portfolio?
What is efzofitimod?
Who can investors contact for more information?
What recent strategic addition did aTyr Pharma make?
When will aTyr Pharma's ticker symbol change take effect?
What is the focus of aTyr Pharma's key programs?
